Brazilian workshop model to train investigators in chronic graft-versus-host disease clinical trials according to the 2005-2006 National Institutes of Health recommendations by Tavares, Rita de Cássia Barbosa da Silva et al.
358                                                                                                                                             Rev Bras Hematol Hemoter. 2011;33(5):358-66
Brazilian workshop model to train investigators in chronic graft-versus-host




Center, Instituto Nacional do
Cancer – INCA, Rio de Janeiro, RJ,
Brazil
2
Universidade Federal do Rio de




Campinas – UNICAMP, Campinas,
SP, Brazil
4
Universidade Federal do Paraná –
UFPR, Curitiba, PR, Brazil
5
Hospital Amaral Carvalho, Jaú, SP,
Brazil
6
Division of Clinical Research,
Fred Hutchinson Cancer Research
Center and University of
Washington School of Medicine,
Seattle, USA
Rita de Cássia Barbosa da Silva
Tavares1
Márcia de Matos Silva1





Maria Elvira Pizzigatti Correa3






Mary Evelyn Dantas Flowers6
Background: The lack of standardization of clinical diagnostic criteria, classification and severity
scores of chronic graft-versus-host disease led the National Institutes of Health to propose consensus
criteria for the purpose of clinical trials.
Method: Here we describe a one-day workshop model conducted by the Chronic Graft-versus-Host
Disease Brazil-Seattle Consortium Study Group to train investigators interested in participating in
multicenter clinical trials in Brazil. Workshop participants included eight transplant physicians, one
dermatologist, two dentists, three physical therapists and one psychologist from five institutions.
Workshop participants evaluated nine patients with varying degrees of severity of mucocutaneous
lesions and other manifestations of the disease followed by a training session to review and discuss
the issues encountered with the evaluation and scoring of patients and in the methods used to evaluate
grip strength and the 2-minute walk test.
Results: Most participants had difficulties in rating the percentage of each type of mucocutaneous
lesion and thought 20 minutes was insufficient to evaluate and record the scores of each patient using
the National Institutes of Health criteria and other cutaneous assessments. Several specific areas of
difficulties encountered by the evaluators were: 1) determining the percentage of erythema in movable
and non-movable sclerosis, 2) whether to score all cutaneous findings in a particular area or just the
dominant lesion; 3) clarification of the definition of poikiloderma in chronic graft-versus-host disease;
4) discrepant interpretation of the mouth score and 5) clarification on the methodology used for the
evaluation of grip strength and the 2-minute walk tests.
Conclusions: Results of this workshop support the need to train investigators participating in clinical
trials on chronic graft-versus-host disease.
Keywords: Graft vs. host disease/diagnosis; Graft vs. host disease/classification; Hematopoietic
stem cell transplantation; Training
Introduction
Chronic graft-versus-host disease (GvHD) remains the major cause of late mortality
after allogeneic hematopoietic stem cell transplantation (HSCT) and accounts for major
impairment in the quality of life of long-term survivors. Disease manifestations result from
tissue insult from interactions between antigen-presenting cells of the recipient and T
lymphocytes of the donor. Some manifestations of chronic GvHD resemble autoimmune
disorders such as scleroderma, Sjogren's syndrome, primary biliary cirrhosis, bronchiolitis
obliterans, chronic immunodeficiency and immune cytopenias.(1,2) Chronic GvHD is a
syndrome with various manifestations and clinical courses, making the diagnosis, staging
and when to start systemic immunosuppression difficult to standardize. Moreover, response
criteria to determine treatment efficacy have remained a major area of research which were
revived by the National Institutes of Health (NIH) consensus project in 2005-2006.(3-5)
The NIH consensus criteria for the diagnosis of chronic GvHD for clinical trial purposes
was proposed in 2005 and include defining minimum criteria for the initial clinical diagnosis,
grading of severity of the sites involved and of the overall severity of chronic GvHD.(3)
According to the NIH criteria, the initial diagnosis requires the presence of clinical
manifestations found exclusively in chronic GvHD. The NIH classification subdivides GvHD
into two categories according to the type of manifestations: acute GvHD ('classic' - acute
GvHD manifestations occurring before day 100 and 'late acute' - acute GvHD manifestations
occurring after 100 days post transplant) and chronic GvHD (classic - signs and symptoms
only found in chronic GvHD with no features of acute GvHD and overlap syndrome -
concurrent manifestations of acute and chronic GvHD at any time). The NIH also proposed
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a categorical score from 0 to 3 according to the severity of
each organ involved (skin, mouth, eyes, gastrointestinal tract,
liver, joints and fascia, lungs and genital tract). The overall
severity of chronic GvHD by the NIH criteria is stratified as
mild, moderate or severe and is dependent of the number of
organs involved and the categorical severity scores given to
each organ.(3)
The Brazilian Society of Bone Marrow Transplantation
held a consensus meeting in June 2009 to establish general
guidelines and recommendations for the diagnosis and
classification of chronic GvHD for clinical trials according to
the NIH consensus project.(6)
In 2008, a consortium was established between five
Brazilian institutions and specialists from the Fred Hutchinson
Cancer Research Center (Seattle), with the purpose of
developing collaborative research in HSCT such as the Brazil-
Seattle Chronic GvHD Study Group (GeDECH). The Brazilian
participating centers of the GeDECH are the Instituto Nacional
de Câncer (INCA), Universidade de Campinas (Unicamp),
Universidade Federal do Paraná (UFPR), Universidade Federal
do Rio de Janeiro (UFRJ) and Hospital Amaral Carvalho. The
GeDECH is a multidisciplinary team of  HSCT physicians, a
dermatologist, a psychiatrist, psychologists, dentists, physical
therapists, nurses, an epidemiologist and a data manager. A
multicenter pilot study on the feasibility of applying the criteria
of the NIH consensus by the GeDECH was presented at the
American Society for Blood and Marrow Transplantation in
2010(7) and is now in press.(8)
The GeDECH is also participating in a prospective
international multicenter study to validate the proposed
criteria for diagnosis, classification and staging according to
the NIH, with Dr. Stephanie Lee and Mary Flowers
coordinating the study in Seattle. This study was approved
by the Research Ethics Committee of each institution and by
the Brazilian National Council of Ethics in Research.
Here we describe a one-day chronic GvHD workshop
model conducted by the GeDECH at the Instituto Nacional
do Cancer (INCA) for the purpose of training investigators
interested in prospective multicenter clinical trials to evaluate
the NIH criteria for diagnosis, classification and staging of
chronic GvHD in Brazil and to identify any difficulties in the
use of the instruments to evaluate manifestations of chronic
GvHD in the skin and other organs for future studies.
Materials and methods
The one-day chronic GvHD Workshop study was
organized by a multidisciplinary team involving a
dermatologist, bone marrow transplant physicians, a dentist
and a physical therapist from the GeDECH at INCA.
Workshop participants included eight transplant physicians,
one dermatologist, two dentists, three physical therapists
and one psychologist from five institutions.
This workshop was approved by the INCA's
Institutional Review Board. Informed consent was obtained
from all nine patients with chronic GvHD to allow clinical
evaluations by several workshop participants and from an
additional three patients for the grip strength and 2-minute
walk tests. Photographs of the patients' skin and mouth were
also obtained previously and were identified only by case
numbers to be used in the training session after the clinical
evaluation during the workshop. Also, a summary of the
medical history of each case was available including: date of
birth, diagnosis, transplantation date, cell source, donor type
and gender, HLA compatibility, conditioning regimen, grade
of acute GvHD, chronic GvHD diagnosis date, type of onset,
sites involved, current treatment and description of recent
manifestations concerning skin, mouth, eyes, gastrointestinal
tract, liver, lungs and genital tract, results of relevant biopsies
and functional assessment by Karnofsky performance status
(KPS) or Lansky performance status (LPS) scales. Chronic
GvHD forms were used to evaluate and score the skin, mouth,
range of movements of joints and overall severity of chronic
GvHD according to the NIH and other evaluation tools
translated into Portuguese.
The tools used in the workshop to evaluate chronic
GvHD are shown in Annexes 1 and 2 and included: 1) the NIH
categorical skin and oral cavity scores (0-3) based on type of
manifestation, extent of involvement, symptoms and degree
of severity affecting activities of daily living; 2) skin response
tool which scores 8 body regions according to percentage of
body surface area (BSA) involved with erythema, moveable
sclerosis and non-moveable sclerosis; 3) the Vienna Skin Scale
tool which scores 10 body regions with percentage
involvement of pigmentary changes, lichen planus-like
lesions and sclerosis (scores of each region are summed for
a total Vienna Skin Score of 0-50; 4) the Hopkins Skin
Sclerosis Score (0-4) and Fascia Score (0-3), the GeDECH
additional Oral Score and 5) the Range of Motion of Joints
Scores. All the scoring forms (Annex 1) and the overall
chronic GvHD score (Annex 2) were attached to the summary
of each patient to be completed by the evaluator of each
patient during the workshop session.
Before the practical evaluation of each case, workshop
participants (evaluators) received a quick explanation of the
program and received a package with the summary of each
case and the chronic GvHD scoring sheets. For the initial
workshop session, patients were divided into two shifts and
distributed between four consultation rooms. Groups of three
evaluators per patient room were formed to evaluate and
complete the chronic GvHD scoring sheets in twenty minutes
per patient.
The dentist (MEC) accompanied each evaluator group
after their initial practical evaluation to provide additional
training on the oral exam, answered questions and pointed
out oral lesions missed by the evaluators during the initial
session.
The second session was conducted by two physical
therapists to demonstrate the grip strength and the 2-minute
walk tests in three patients. The grip strength test was
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performed with the hydraulic hand dynamometer with the
patient using the dominant hand, seated with the elbow bent
at 90°, shoulder and forearm in neutral position, wrist slightly
extended, with three measurements of the maximum force
reached in kilograms recorded by the pointer. The device was
reset after each measurement. Finally, an average was
calculated and compared to standard values for age and gender.
The 2-minute walk distance test was performed on a 20 meter
range track, marked at the beginning, every two feet and at the
end. Patients had a rehearsal to understand the procedure and
were placed at the start tag. One physical therapist encouraged
them to walk as fast as possible and walked next to them all the
way, while the other advised the time of departure, when the
clock marked one minute and again 15 seconds from the end,
and recorded the number of 'laps' in order to calculate the total
distance in feet walked in 2 minutes.
The final session of the workshop consisted of a training
session by the dermatologist (MM) and physical therapist
(CS). The dermatologist presented photos of skin lesion
types and percentage of affected area of each case and
opened the discussion on a comparison of scoring between
participants (evaluators) and the dermatologist's rating. The
physical therapist clarified the methodology recommended by
the NIH Consensus for functional assessment in particular
about the grip strength and the 2-minute walk tests.
Results
The workshop was held on 30/7/2010 in Rio de Janeiro
(CEMO/INCA) and included the evaluation of 9 patients by
14 multidisciplinary evaluators from 5 institutions. Patient
demographic, transplant and chronic GvHD data of the nine
cases evaluated during the workshop are shown in Tables 1
and 2.
The first session of the workshop included the
evaluation of nine patients during 3.5 hours. Most of the
evaluators thought that 20 minutes per patient was insufficient
to read the medical summary, obtain the clinical evaluation
and complete the chronic GvHD scoring forms.
Participants reported no problems with the scoring of
joint movements and how to apply the "rule of 9" to record
the percentage of affected cutaneous area of each body
region. However, most evaluators had difficulties in scoring
the fraction of erythema in movable and non-movable
sclerosis according to the Vienna Score System (Grade 3 and
4) and assigning the percentage of BSA affected by certain
types of skin lesions.
Participants observed the grip strength and 2-minute
walk tests performed with three patients by the two physical
therapists. Disagreement between the physical therapists
from two different institutions on the methodology used to
evaluate the 2-minute walk test was noted such as whether
or not to encourage the patient to walk faster, the necessity
or not to walk together with the patient during the entire test
and setting standards in the methodology used in the grip
strength test. Such discrepancies were later reconciled by
standardizing the methodology for future multicenter studies.
After the conclusion of the clinical evaluation of the
workshop, patients were invited to a lunch meeting with a
psychologist from the transplant center to discuss about
their workshop experience. Patients indicated that the
workshop was what they had expected and that they were
glad to have been able to contribute to this training session.
In addition to time limitations to evaluate and complete
the scoring forms of each patient, specific difficulties in
determining the percentage of BSA associated with certain
types of skin and mouth lesions were discussed, reviewed
and reconciled during the training sessions that followed the
practical evaluation session.
Specific areas of difficulties and need for clarification
identified during the training session included: a) determining
the fraction of erythema in movable and non-movable
sclerosis, (Figure 1); b) scoring all elements of cutaneous
features (i.e., hypochromia, hyperpigmentation, erythema and
not only the diagnostic manifestations of chronic GvHD of a
particular area (i.e., lichen planus-like lesions, cutaneous
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sclerosis) illustrated in Figure 2; c) how to score poikiloderma
using the Vienna Score Scale when color changes are not
associated with sclerosis (Grade 1?) versus when
poikiloderma is secondary to moveable sclerosis (Grade 3?) -
illustrated in Figure 3; d) where to record the percentage of
BSA affected by keratosis pilaris like rashes in the NIH
response criteria tool (erythema?); e) how to record erythema
when attributed to phototherapy (PUVA) or other causes
other  than chronic GvHD - should it be described separately
from the chronic GvHD scoring?; f) clarification for the
definition of "back" in the study to include the entire back
and buttocks; g) clinical interest in scoring lip atrophy and
restrictions in mouth opening from sclerosis (Figure 4); h)
lack of an objective evaluation of xerostomia by the NIH
scoring criteria of the mouth (i.e., the absence of sublingual
lake is not noted(9)); i) better definition to score the degree of
limitations in oral intake (i.e., not significant, partially or
Figure 1 – Erythema over
movable and non-movable
sclerosis related to chronic
GvHD. Example of a case to
illustrate the potential
difficulty on how to rate the
fraction of erythema over the
affected areas of sclerosis
Figure 2 – Cutaneous manifestations of chronic GvHD to illustrate the
importance of complete skin examination (i.e., color changes, shape
of lesion, surface, thickness and mobility). Example of a case difficult
to rate with various skin manifestations in each affected area
Figure 3 – Illustration of
poikiloderma which may be
difficult to score in the
absence of sclerosis
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criteria to evaluate treatment response.(4) A large prospective
multicenter clinical trial in chronic GvHD is underway in North
America(11) and in other countries including Brazil to validate
several NIH proposed tools to evaluate chronic GvHD and
determine their impact on major chronic GvHD-related
outcomes (i.e., overall survival, relapse, non-relapse mortality,
duration of immunosuppression, quality of life, etc.) compared
to other evaluation measurements including the Skin and
Fascia Scores by Johns Hopkins and the Vienna Skin Scale.(12)
Some of the results from this multicenter clinical trial have
been published or are in press.(13,14)
Our workshop was well received and viewed as an
appropriate model to evaluate chronic GvHD using the NIH
and other measurement tools and to train investigators
interested in participating in clinical trials in Brazil. In this
workshop, evaluators had difficulties in scoring the extent of
involvement of certain types of skin manifestations. As
reported by others,(12,15) variability in the chronic GvHD
scoring were also noted using the NIH and other scoring
measurement tools, but results of the inter and intra-evaluator
variability improved with subsequent training. The time
required for adequate evaluation and completion of various
tools used to score chronic GvHD in the current workshop
was greater than 20 minutes per patient. However, time to
evaluate and score patients with chronic GvHD may be
shorter for physicians who follow their own patients and
with increased experience in using the scoring tools.
One objective evaluation missing in the current NIH
and other available tools noticed by the dentist is the scoring
of xerostomia and oral mucosa atrophy, resulting in a gap in
the oral assessment of chronic GvHD that may underestimate
the oral score.
Difficulties in scoring certain types of skin manifestations
were noted. For instance, evaluation of erythema in patients
receiving PUVA could result in an overestimation of erythema
not related to chronic GvHD. The point was made that erythema
caused by photochemotherapy such as PUVA(16,17) is usually
diffuse, non-pruritic and limited to treatment-exposed areas
that often resolves within 48 to 72 hours.
Another area of difficulty was in scoring poikiloderma
(atrophic with pigmentary skin changes) using the Vienna Skin
Scale. For example, a patient with hypo- and hyper-pigmentation
and erythema without sclerosis would be scored as Grade 1
but as Grades 3-4 if the poikiloderma is secondary to sclerosis
(movable or non-movable). Therefore, recognizing the
diagnosis of chronic GvHD lesions is critical for adequately
scoring the skin according to the Vienna Skin Scale.
Another teaching point by the dermatologist (MMS)
about the Vienna Skin Scale was on how to recognize skin
lichen planus-like lesions and cutaneous sclerosis in hyper-
or hypo-pigmentation areas. Considering that hyper- and
hypo-pigmentation are often associated with diagnostic
cutaneous manifestations of chronic GvHD, such lesions
should be scored in the Vienna Skin  Scale as either Grade 2
(lichen-planus like presentation) or Grade 3 or Grade 4 if,
Figure 4 – Lip atrophy and restriction of mouth opening from sclerosis
severe); j) clarification between the overall severity of chronic
GvHD by evaluators as a qualitative rating based on clinical
impression and thus independent from the NIH categorical
severity scores of each organ - for instance a patient with
only non-moveable score affecting less than 10% of total
BSA as the only manifestation of chronic GvHD would be
rated with mild overall severity by the physician and would
have a skin score of 3 by the NIH categorical organ scale
because of the non-moveable sclerosis; k) Clarification on
the methodology for the 2-minute walk due to discrepant
interpretation between the physical therapists of two different
centers (i.e., whether to encourage or not the patient verbally
or by walking together during the test or, to only walk with
the patient to show the course as part of the explanation
about the 2 minute test prior to testing). Both the grip strength
and the walk tests were thought to be important measures to
evaluate functional performance of patients with chronic
GvHD and feasible tests to be conducted in clinical trials.
Teaching points on Oral Medicine (MEC) during the
training session was the basic evaluation of the mouth to score
the four clinical signs of chronic GvHD including:
hyperkeratotic plaques, ulcers, erythema and mucocele.
Hyperkeratotic plaques, ulcers and erythema manifestations
should be evaluated on the lips, labial mucosa, buccal mucosa,
tongue and soft palate, while mucocele only on labial mucosa
and soft palate.(9) All oral lesions should be scored according
to the percentage of total area affected by each lesion. For the
subjective evaluation of oral symptoms, complaints of dry
mouth, altered taste, pain and tenderness with or without
limitations in oral ingestion are considered. It is important to
note that the definition of oral sensitivity is related to spicy
food ingestion or use of toothpaste, therefore distinct from
mouth pain, which is recorded separately in another scale.
Discussion
The NIH consensus scoring system proposed
standardized criteria in the diagnosis of chronic GvHD for
clinical trials that require clinical manifestations exclusively
found in chronic GvHD (not present in acute GvHD).(10) In
addition, the NIH proposed a 0-3 categorical score to assess
severity of each organ involved but also developed new
Rev Bras Hematol Hemoter. 2011;33(5):358-66                                                                                                                                           363
respectively, movable or non-movable sclerosis is present.
Variability in the scoring of chronic GvHD represents a
limitation of available tools with potential impact on the
interpretation of results in multicenter clinical trials.
Appropriate training of investigators is therefore necessary
in the utilization of the scoring tool chosen for consistency
of the evaluator, especially in studies aimed to evaluate the
extent and types of skin involvement of chronic GvHD.
This workshop was useful to clarify several questions
related to the NIH and other evaluation tools that are used in
studies of chronic GvHD. The feasibility of this study
motivated the GeDECH to put together a similar education
workshop session during the annual meeting of the Brazilian
Society of Bone Marrow Transplantation in August 2011 to
expand the training of new investigators interested in
participating in future GeDECH studies. The second
workshop had more than 30 participants from more than 8
institutions and was well received.
Conclusion
The 2005-2006 NIH chronic GvHD criteria for clinical
diagnosis, staging and other proposed measures to evaluate
treatment response in clinical trials represent an important
first step towards the development of better treatment and to
improve survival and quality of life of affected patients. We
demonstrated the feasibility of conducting a workshop on
the NIH chronic GvHD tools and other cutaneous measures
as a model to evaluate and train Brazilian investigators
participating in multicenter clinical trials.
Several areas of difficulties in the evaluation of patients
with chronic GvHD according to the NIH and other tools
were identified. Results of this workshop support the need
of training investigators interested in participating in future
chronic GvHD clinical trials and suggest the need for
simplifying current tools to evaluate chronic GvHD especially
regarding the cutaneous involvement measurements.
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 – Poikiloderma – combines reticulated pattern and epidermal
atrophy. It is common to observe simultaneous erythema, and hyper-
and hypo-pigmentation. It is a dermatological alteration of
pigmentation.
– Lichen planus-like lesions – erythematous-violaceous papules
that may form annular plaques. Often, there are whitish lines on the
surface (Wickham striae) similar to those of idiopathic lichen planus.
Oral lesions may be presented in a reticular, plaque, atrophic, erosive
and bullous pattern.
– Movable lichen sclerosus-like lesions – change in skin texture,
decreased skin turgor (skin looks like cigarette paper); lesions are
grouped into gray to white movable plaques.
– Morphea-like sclerotic features – localized patchy areas of
fibrosis of the dermal tissue, often with dyspigmentation. Although
the skin is movable, there is a decrease in the possibility of pinching.
– Non-movable sclerosis – deep sclerosis features without the
possibility of pinching or mobilization.
– Fasciitis – skin surface may have varying degrees  of fibrosis or be
normal, depression marks are seen troughout the course of the tendons
with reduced range of motion; inability to assume a "prayer posture".
– Depigmentation (vitiligo-like) – the achromia appears isolated
after lichen planus-like manifestations or on the top of an
inflammatory healing process such as zoster. It can be segmental or
generalized.
– Follicular keratosis – erythematous papules with perifollicular
corneal plugs inside the follicle opening.
– Hyperpigmentation – pigmentary change without sclerosis. No
active erythema.
– Maculo-papular rash – erythematous papules (3-4 mm) that
converge; often scaly, seen with both acute and chronic GvHD or
after lymphocyte infusion.
– PUVA – treatment using total body irradiation with ultraviolet A
combined with prior oral photosensitizing (psoralen)
– Mucocele – term used for leakage or retention of mucus.
– Xerostomia – complaint of dry mouth due to lack of saliva.
– Hyposalivation – decreased amount of saliva in the mouth.
Glossary
Anexos
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